Patents by Inventor Hiroaki Shitama
Hiroaki Shitama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11802135Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.Type: GrantFiled: November 3, 2021Date of Patent: October 31, 2023Assignees: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Maiko Hamada, Yuki Arai, Shuhei Yamakoshi, Hiroko Wada, Kazufumi Otsuki, Hiroaki Shitama, Nobuyuki Takakura
-
Publication number: 20230146210Abstract: The present invention aims to provide a compound acting as a specific agonist for LPA4 receptors, and a pharmaceutical composition containing the compound. The present invention relates to a novel lysophosphatidic acid derivative having an agonistic action on LPA4 receptors and useful for the prophylaxis and/or treatment of diseases associated with angiogenesis abnormalities involving LPA4 receptors, diseases associated with vascular disorders, or the symptoms associated therewith, and a pharmaceutical composition containing the derivative.Type: ApplicationFiled: November 3, 2021Publication date: May 11, 2023Applicants: MITSUBISHI TANABE PHARMA CORPORATION, OSAKA UNIVERSITYInventors: Maiko HAMADA, Yuki ARAI, Shuhei YAMAKOSHI, Hiroko WADA, Kazufumi OTSUKI, Hiroaki SHITAMA, Nobuyuki TAKAKURA
-
Patent number: 9981960Abstract: The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 28, 2015Date of Patent: May 29, 2018Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuo Yamamoto, Atsushi Sato, Kenji Morokuma, Hiroaki Shitama, Takashi Adachi, Masahiko Miyashiro
-
Patent number: 9975871Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 22, 2016Date of Patent: May 22, 2018Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro
-
Publication number: 20170190697Abstract: The present invention relates to a novel pyrrolidine compound having melanocortin receptor agonist activity or a pharmaceutically acceptable salt thereof, and to pharmaceutical applications thereof. The present invention relates to a pyrrolidine derivative represented by formula [I], wherein ring A represents an optionally substituted aryl group or the like; R1 represents an optionally substituted alkyl group or the like; R2 represents a halogen atom or the like; and R3 is an alkyl group substituted with an optionally substituted aryl group or the like, and R4 is a hydrogen atom or the like; or R3 and R4 are terminally attached to each other, and together with the nitrogen atom to which they are attached, form an optionally substituted nitrogen-containing aliphatic heterocyclic ring that may partially contain a double bond; or to a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 28, 2015Publication date: July 6, 2017Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Yasuo YAMAMOTO, Atsushi SATO, Kenji MOROKUMA, Hiroaki SHITAMA, Takashi ADACHI, Masahiko MIYASHIRO
-
Publication number: 20160272614Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 22, 2016Publication date: September 22, 2016Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu SAKURAI, Kunio SARUTA, Norimitsu HAYASHI, Takashi GOI, Kenji MOROKUMA, Hidekazu TSUJISHIMA, Hiroaki SAWAMOTO, Hiroaki SHITAMA, Ritsuo IMASHIRO
-
Patent number: 9302996Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 16, 2011Date of Patent: April 5, 2016Assignee: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro
-
Publication number: 20130261128Abstract: This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 16, 2011Publication date: October 3, 2013Applicant: MITSUBISHI TANABE PHARMA CORPORATIONInventors: Osamu Sakurai, Kunio Saruta, Norimitsu Hayashi, Takashi Goi, Kenji Morokuma, Hidekazu Tsujishima, Hiroaki Sawamoto, Hiroaki Shitama, Ritsuo Imashiro